NCI-H889 Cells
USD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | NCI-H889 is a human small cell lung cancer (SCLC) cell line with neuroendocrine features. It was established from an adult patient and is categorized as a classic SCLC model based on morphological and molecular criteria. The cells grow in suspension and display the round-to-oval morphology typical of SCLC. NCI-H889 expresses several neuroendocrine markers and has been widely used in mechanistic and pharmacologic studies related to this aggressive lung cancer subtype. Functionally, NCI-H889 is characterized by autocrine signaling through the insulin-like growth factor II (IGF-II) and its receptor IGF-R. While IGF-I mRNA is widely detected among lung cancer cell lines, direct secretion of IGF-I protein is rare; in NCI-H889, the predominant ligand involved in growth stimulation is IGF-II. This is consistent with findings that support IGF-II/IGF-R signaling loops as key drivers of autocrine growth in SCLC cell lines. These autocrine interactions make NCI-H889 a valuable system for studying IGF-mediated mitogenic signaling and its therapeutic disruption. Epigenetic analyses of NCI-H889 have also provided insight into the regulation of drug response. Methylation profiling indicates alterations in several genes involved in DNA damage response, cell cycle regulation, and transcriptional control. For example, NCI-H889 has been included in studies showing differential methylation and expression of genes like SLFN11, which is associated with sensitivity to DNA-damaging agents, and EZH2, a histone methyltransferase frequently upregulated in SCLC. These characteristics collectively position NCI-H889 as a relevant preclinical model for exploring therapeutic vulnerabilities associated with neuroendocrine lung tumors. |
|---|---|
| Organism | Human |
| Tissue | Metastatic |
| Disease | Lung small cell carcinoma |
| Metastatic site | Lymph node |
| Synonyms | H889, H-889, NCIH889 |
Characteristics
| Age | 69 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Epithelial |
| Cell type | Epithelial like |
| Growth properties | Clusters in suspension |
Regulatory Data
| Citation | NCI-H889 (Cytion catalog number 305842) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1598 |
Biomolecular Data
| Mutational profile | Mutation: TP53, Simple, p.Cys242Ser (c.725G>C), Unspecified (PubMed=1312696, PubMed=1565469). |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
| Metastatic site: | Lymph node |
|---|
-
Related products
Related products